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Plaque excision with the Silverhawk catheter: Early
results in patients with claudication or critical limb
ischemia
W. Brent Keeling, MD, Murray L. Shames, MD, Patrick A. Stone, MD, Paul A. Armstrong, DO,
Brad L. Johnson, MD, Martin R. Back, MD, and Dennis F. Bandyk, MD, Tampa, Fla
Objective: This study was conducted to detail the early experience after infrainguinal atherectomy using the Silverhawk
plaque excision catheter for the treatment of symptomatic peripheral vascular disease.
Methods: A prospective database was established in August 2004 in which data for operations, outcomes, and follow-up
were recorded for patients undergoing percutaneous plaque excision for peripheral arterial occlusive disease. Society for
Vascular Surgery (SVS) ischemia scores and femoropopliteal TransAtlantic Inter-Society Consensus (TASC) criteria were
assigned. A follow-up protocol included duplex ultrasound surveillance at 1, 3, and 6 months and then yearly thereafter.
Standard statistical analyses were performed.
Results: During a 17-month period, 66 limbs of 60 patients (37 men [61.7%]) underwent 70 plaque excisions (four
repeat procedures). Indications included tissue loss based on SVS ischemia at grades 5 and 6 (25/70), rest pain at
grade 4 (22/70), and claudication at grades 2 to 3 (23/70). The mean lesion length was 8.8  0.7 cm. The technical
success rate was 87.1% (61/70). Adjunctive treatment was required in 17 procedures (24.3%), consisting of 14
balloon angioplasties and three stents. Femoropopliteal TASC criteria included 5 TASC A lesions, 14 TASC B
lesions, 32 TASC C lesions, and 19 TASC D lesions. Although 17 plaque excisions included a tibial vessel, no patient
underwent isolated tibial atherectomy. The mean increase in ankle-brachial index was 0.27  0.04 and in toe
pressure, 20.3  6.9 mmHg. Mean duplex ultrasound follow-up was 5.2 months (range, 1 to 17 months). One-year
primary, primary assisted, and secondary patency was 61.7%, 64.1%, and 76.4%, respectively. Restenosis or occlusion
developed in 12 patients (16.7%) and was detected at a mean of 2.8  0.7 months. Restenosis or occlusion was
significantly more common (P < .05) in patients with TASC C and D lesions compared with patients with TASC A
and B lesions. Six (8.3%) of 12 patients underwent reintervention on the basis of duplex ultrasound surveillance
results. Four (33.3%) of 12 patients experienced reocclusion during the same hospitalization, and amputation and
open revascularization were required in two patients each.
Conclusions: Percutaneous plaque excision is a viable treatment option for lower extremity revascularization. Outcomes
are related to ischemia and lesion severity. Patency and limb salvage rates are equivalent to other endovascular modalities.
(J Vasc Surg 2007;45:25-31.)Traditional surgical therapies for infrainguinal pe-
ripheral arterial occlusive disease have centered on bypass
of diseased vessels to distal targets. These procedures are
often complicated by lack of suitable conduit, high rates
of wound complications, and have a reintervention rate
of up to 28%.1,2 With the advances in catheter-based
interventions, endovascular techniques are commonly
being used as alternatives to open infrainguinal bypass
procedures. To date, infrainguinal disease has been man-
aged, with varying degrees of success, with balloon an-
gioplasty, stenting, cryoplasty, laser, and excisional
atherectomy.
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doi:10.1016/j.jvs.2006.08.080In a study detailing long-term patency of superficial
femoral artery (SFA) angioplasty and stenting, primary
patency was demonstrated in 52% of patients at 5 years of
follow-up.3 Angioplasty of infragenicular arteries has also
been practiced with some degree of success. Although
primary patency was only 23.5% for infragenicular vessels,
limb salvage was 77.3% in one series.4 Both studies found
that periprocedural failure or resultant occlusion, or both,
was dependent on Transatlantic Inter-Society Consensus
(TASC) criteria. TASC D lesions demonstrated lower pa-
tency rates and lower rates of limb salvage for below knee
lesions, and primary patency of SFA lesions was lower in
TASC C and D lesions.3,4
Our purpose in this report was to add to the mounting
body of data on the Silverhawk Plaque Excision Catheter
(Fox Hollow Technologies, Inc, Redwood City, Calif) by
publishing our early results. In addition, by using reporting
standards common to vascular surgeons, including the
Society for Vascular Surgery (SVS) ischemia grading system
and the TASC criteria for femoropopliteal lesions, we
sought to identify risk factors for reocclusion. We hy-
pothesized that TASC criteria for femoropopliteal lesions
would assist in predicting early reocclusion after successful
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hawk catheter.
METHODS
Patient population. From August 2004 to January
2006, all patients who were treated with the Silverhawk
Plaque Excision Catheter were enrolled in a prospective
database. Patients scheduled for atherectomy in whom the
lesion could not be crossed or in whom the Silverhawk
device could not be passed were excluded from analysis. All
plaque excisions were performed by a single vascular sur-
geon (M. L. S.). Patients with isolated tibial infrageniculate
disease were not considered for this study.
Data on demographics, operative details, outcomes,
and follow-up were gathered from hospital, office, and
vascular laboratory records and included in the computer-
ized database. This study was not sponsored directly by
industry, but some patients in the series were treated as a
part of physician training programs sponsored by Foxhol-
low, Inc.
Atherectomy technique. Atherectomy was per-
formed in the operating room using portable imaging
equipment (OEC 9800M; General Electric Healthcare,
Waukesha, Wisc). Procedures were performed via a con-
tralateral (40/70) or ipsilateral (30/70) approach through
a 7F introducer sheath. Arteriography was performed ini-
tially to determine the extent of disease and delineate tibial
runoff in patients where computed tomography angiogra-
phy or magnetic resonance angiography was not available
preoperatively.
A combination of a straight stiff Glidewire (Terumo
Medical Corp, Somerset, NJ) and angled Glidecath
(Terumo Medical Corp) were used to traverse occluded
vessels. Once the lesion was crossed and re-entry into the
true lumen was confirmed with contrast injection, a
0.014-inch guidewire was placed. Systemic anticoagula-
tion was initiated with intravenous heparin sodium (100
IU/kg).
The Silverhawk device was then selected based on the
target vessel size and location. For tibial lesions or vessel
diameter 3 mm, an SS or ES device was used, and a
vessel diameter of 3 to 5 mm required an SX device.
Calcified lesions or distal popliteal lesions were treated
with an MS device and SFA lesions, with an LS, LS-F, or
LX catheter.
After atherectomy, focal dissections without hemody-
namic disturbance were treated with low-pressure (4 atm)
balloon dilation to approximate the intima. For significant
residual stenosis30% not amenable to repeat atherectomy
or hemodynamically significant dissections, stenting was
performed with nitinol self-expanding stents. Pressure gra-
dients or intraoperative duplex evaluation was performed if
hemodynamic improvement was questionable. All patients
were treated with clopidogrel bisulfate, 75 mg daily, after
intervention.
Hemodynamic evaluation. Arterial testing before
and after intervention was performed at a laboratory regis-tered by the Inter-societal Committee for the Accreditation
of Vascular Laboratories. Atherectomy site surveillance was
initiated in the outpatient clinic with clinical examination
2 weeks, and ankle-brachial index (ABI) and duplex
ultrasound arterial imaging at 1, 3, and 6 months, and then
yearly. Indications for repeat intervention included recur-
rent symptoms with a drop in ABI of 0.15, duplex-
detected stenosis (peak systolic velocity 300 cm/s, velocity
ratio across the lesion of 3.5), or 70% stenosis by CT
angiography, magnetic resonance angiography, or contrast
arteriography.
Data analysis. The attending surgeon reviewed all
intraoperative angiograms, and lesions were assigned a
femoropopliteal TASC category. Success of plaque exci-
sion was defined according to the SVS and the Interna-
tional Society for Cardiovascular Surgery reporting stan-
dards.5
Statistical analysis. The tests used were Student’s t test
to evaluate continuous variables (Excel,Microsoft Corp, Red-
mond, Wash), Fisher’s exact test for binomial variables
(http://www.matforsk.no/ola/fisher.htm), Kaplan-Meier
calculations and life tables (http://www.hutchon.net/
Kaplan-Meier.htm), and log-rank tests for comparison of pa-
tency results (http://bioinf.wehi.edu.au/software/russell/
logrank/). All results were expressed as mean  SEM when
appropriate. P .05 were considered significant.
RESULTS
During the study period, 70 plaque excisions were
done in 66 limbs of 60 patients (37 men, 61.7%), including
six patients with bilateral disease and four patients with
recurrent disease. Twenty-seven patients (45.0%) had dia-
betes mellitus, 22 patients (36.7%) were smoking at the
time of their intervention, 6 (10.0%) were in end-stage
renal failure requiring dialysis, and 6 (10.0%) had failed
previous lower extremity bypass procedures (one SFA
stent).
Indications for intervention included tissue loss repre-
sented by SVS ischemia grades of 5 and 6 (25/70; 35.7%);
rest pain, SVS grade 4 (22/70; 31.4%), and claudication,
SVS grades 2 to 3 (23/70; 32.9%). Mean preoperative ABI
of the affected limb was 0.53  0.03, and mean toe
pressure was 41.3  5.7 mm/Hg.
Atherectomized arterial segments included the com-
mon femoral artery in 1, the superficial femoral artery
(SFA) in 52, the popliteal artery in 29, and the tibial arteries
in 17. Mean plaque excision length was 8.9  0.8 cm
(range, 2 to 30 cm), and 23 plaque excisions (32.9%) were
10 cm. Local anesthesia was used in 40 procedures
(57.1%).
Femoropopliteal TASC criteria included 5 TASC A
lesions (7.1%), 14 TASC B lesions (20.0%), 32 TASC C
lesions (44.3%), and 19 TASCD lesions (27.1%). Fourteen
procedures (20.0%) required adjunctive balloon angio-
plasty at the site of plaque excision, and three procedures
(4.3%) required adjunctive stent placement.
nsus;
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embolization, which resulted in the failure of five proce-
dures (7.0%), was treated successfully with either suction
embolectomy or intravascular tissue plasminogen activator.
There were four repeat atherectomies (5.7%). The average
time for plaque excision after crossing the lesion was 40
minutes (range, 15 to 90 minutes). The Silverhawk cathe-
ter was reinserted a mean of four times (range, 1 to 7), with
four to six passes per insertion.
The mean increase in ABI was 0.27  0.04 and the
mean increase in toe pressure was 21.6 7.0 mm/Hg after
plaque excision. Of the 51 patients with ABIs completed
before discharge, 26 (51.0%) had an ABI in the affected
limb of 0.8, and 12 (46.2%) had critical limb ischemia
(CLI) preoperatively.
Average length of stay was 5.7  1.0 days (range, 0 to
38 days), but for 32 procedures (45.7%), patients remained
in the hospital for 23 hours. Mean length of stay was
lengthened by patients who underwent atherectomy for
CLI as part of a prolonged hospital stay.
There were no deaths at 30 days. Major procedural
complications occurred in three patients (5.0%), includ-
ing a perforated common iliac artery during a procedure
that was repaired with covered stent placement, a myo-
cardial infarction, and an operative intervention for a
groin hematoma. There were no perforations of treated
vessels. Three patients required further open revascular-
ization owing to persistent tissue ischemia 1 month of
the atherectomy, even with angiographically patent
atherectomy sites. Of the four patients who experienced
in-hospital reocclusion, three who had SFA atherectomy
only underwent subsequent open distal bypass for ongo-
ing critical ischemia despite angiographically patent
SFAs, and two required amputation during the same
hospitalization.
Twelve plaque excisions (17.1%) reoccluded (n 
11) or restenosed (n 1) and were detected at a mean of
2.8  0.7 months (range, 0 to 10 months), and six
underwent reintervention for restenosis detected by du-
plex ultrasound imaging (Table). Forty-six patients
Table I. Outcomes of failed peripheral plaque excision













SVS, Society of Vascular Surgery; TASC, TransAtlantic Inter-Society Conse(76.7%) entered into a duplex ultrasound surveillanceprotocol, and mean follow-up was 6.1 months (range, 1
to 20 months). Primary, primary assisted, and secondary
patency for the entire cohort was 61.7%, 64.1%, and
76.4% at 1 year. For SVS grades 2 to 3, primary and
secondary patency was significantly improved compared
with SVS grades 4 to 6 (P  .025, and P  .05, Fig 1).
Similarly, when compared by TASC criteria, 6-month
primary patency was significantly less in TASC C and D
lesions than in TASC A and B lesions (P .025, and P
.10, Fig 2).
Four (33.3%) of 12 patients experienced reocclusion
during the initial hospitalization, and two required am-
putations. A total of four patients (6.7%) underwent
amputation (3 below knee amputations; 1 above knee
amputation) of the affected limb. Half of these patients
had patent atherectomy sites but required amputation
for ongoing ischemia without further revascularization
options. Two patients who later underwent amputation
initially refused amputation and were offered atherec-
tomy as a last-ditch alternative. One of these patients had
extensive forefoot tissue loss without options for tissue
reconstruction.
Four patients also required distal open revasculariza-
tion; three of these had angiographically patent atherec-
tomy sites. For patients with CLI (SVS ischemia grades 4
to 6), limb salvage was 86.2% at 12 months (Fig 3).
Patients with TASC C or D lesions (5 and 7 lesions,
respectively) were more likely to reocclude than those
with TASC A and B lesions (0 and 0 lesions). In addition,
patients who experienced reocclusion had a significantly
higher mean SVS ischemia grade (4.9 0.3 vs 3.8 0.1;
P .006). Although no patient underwent isolated tibial
atherectomy, the inclusion of tibial atherectomy (17
total patients; 5 reocclusons) in conjunction with
atherectomy of other infrainguinal arteries demonstrated
a significant increase in the rate of reocclusion (P  .03).
DISCUSSION
The use of endovascular procedures for the treatment
e of failure Treatment Limb loss
mbosis SFA stent No
nosis Repeat atherectomy No
mbosis Repeat atherectomy No
mbosis None No
mbosis Bypass No
mbosis Repeat atherectomy No


















Throof peripheral arterial occlusive disease is widespread and
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group documented a 62% increase in the endovascular
treatment of iliac and infrainguinal lesions during the past 6
Fig 1. Kaplan Meier analysis of primary patency after
ischemia grades 4-6 had statistically decreased pat
Fig 2. Primary patency by TransAtlantyears; the greatest increase being a 10-fold increase ininfrainguinal interventions.6 Despite this trend, several
studies report marginal long-term patency and high rein-
tervention rates for angioplasty, subintimal angioplasty,
e excision by SVS ischemia grades. Patients with SVS
compared with patients with ischemia grades 1-3.
er-Society Consensus (TASC) criteria.plaqu
encyic Intand SFA stent placement.7
g plaq
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 1 Keeling et al 29The Silverhawk catheter is a modification of earlier
atherectomy devices. Prior catheters had balloons built into
their design and were of higher profile. This new genera-
tion device enables improved luminal gain without the
resultant barotrauma associated with balloon angioplasty
and stent placement. Its low-profile monorail design facil-
itates traversal of long-length lesions and repetitive plaque
excision. Catheters are sized to the target vessel lumen for
optimal results.
Previously published reports about the use of this
catheter have conveyed relatively favorable results. Zeller
et al8 reported an 80% patency in primary-treated lesions
at 6 months. The reported mean lesion length treated by
plaque excision was short (4 cm in native vessels), and
the patient cohort was composed primarily of SFA le-
sions in patients with claudication. Atherectomy for
patients with CLI has also had encouraging results by
improving foot perfusion to avoid major amputations.
Data from a prospective evaluation of plaque excision in
69 patients with CLI demonstrated less extensive ampu-
tation than predicted preoperatively in 82% of treated
patients at 6 months.9 Results from the Talon Registry
(Treating Peripherals with Silverhawk: Outcomes Col-
lection), a multicenter Web-based database of Silver-
hawk-treated patients, reported a 1-year freedom from
target lesion revascularization of 81%; however, plaque
excision length was short, and 70% of patients were
treated for claudication symptoms.10
The data presented in this report are unique in a
number of ways. In contrast to prior studies, the patient
cohort included a number of patients with long-segment
plaque excision as well as a large percentage of patients
with CLI. Long-segment plaque excision is feasible.
Atherectomy was offered to all patients with lifestyle-
Fig 3. KaplanMeier analysis of limb salvage rates followinlimiting claudication, rest pain, or tissue loss presentingto the primary investigator (M. L. S.) with superficial
femoral artery occlusive disease. Decisions about actual
treatment were made after angiography and successful
crossing of target lesions.
In our early experience, some patients with focal
disease were treated with primary angioplasty, and
heavily calcified lesions were treated with primary stent-
ing. Lesions not amenable to endovascular therapy (le-
sions that could not be crossed and complex superficial
and tibial occlusive disease) were treated with standard
bypass procedures. During the study period, 61% (70/
115) of the ischemic limbs presenting to the primary
author were treated with percutaneous plaque excision,
10 patients with percutaneous angioplasty only (2 cryo-
plasty), and four with primary stent placement. Twenty
lesions could not be crossed. These patients all were
treated with bypass procedures. An additional 11 pa-
tients were treated with bypass surgery without attempts
at percutaneous revascularization.
Approximately two thirds of patients who underwent
plaque excision for the indications of either rest pain or
tissue loss had SVS ischemia grades of 4, and this also
represents a change from published reports. Patients
undergoing plaque excision demonstrated an average
increase of 0.2 in ABI and 20 mm Hg in toe pressure
after intervention, comparable with results reported after
balloon angioplasty or stent placement.4,11 Clinical im-
provement was apparent in most cases, only four patients
required bypass for ongoing ischemia despite patent
atherectomized segments. These cases likely reflect inad-
equate hemodynamic improvement for wound healing in
patients with significant tissue loss.
Atherectomy, like other endovascular interventions,
can be performed without general anesthesia, reduces
ue excision in patients with critical limb ischemia SVS 4-6.the complications of surgical bypass, and shortens length
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days, with no deaths. Two deaths (2.7%) occurred during
the follow-up period, perhaps reflecting the less invasive
nature of endovascular therapy. Past studies have re-
ported mortality rates of 20% to 27% at 1 year in CLI
patients.12 Our data compare favorably with the 5-year
survival of 56% obtained with balloon angioplasty in CLI
patients.4 Longer follow-up is needed to establish a
survival benefit in this group of patients; clearly, how-
ever, resolution of clinical ischemic symptoms and avoid-
ance of limb amputation would lead to improved quality
of life.
Our prolonged length of stay is a consequence of a
number of procedures being performed on patients hospi-
talized for nonhealing wounds in whom length of stay was
dictated by wound healing. Almost half (45.7%) of the
patients were treated as outpatients, and 60% spent2 days
in the hospital.
In patients with CLI, 12-month primary patency was
36% and secondary patency was 62%. The demographic
characteristics of the patient population may account for
these results: 45% were diabetic, 37% continued to smoke,
and 10% required hemodialysis. Despite the decreased pa-
tency, limb salvage rates at 86.2% at 1 year were comparable
with both bypass and other percutaneous interven-
tions.4,12,13
Reocclusion or restenosis after technically successful
plaque excision occurred in a number of patients. Twelve
atherectomies reoccluded or restenosed, and four oc-
curred during the original hospital stay. These in-hospi-
tal reocclusions likely contributed to the short mean
duration to reocclusion. Four reocclusions in our series
were amenable to repeat percutaneous intervention, and
an additional four were treated with surgical bypass. In
accordance with a previous report detailing mid-term
outcomes of atherectomy-assisted angioplasty, our co-
hort experienced reocclusion at a rate of 16.7% at 6
months.14 We found that reocclusion rates were related
to TASC criteria, and this parallels the experience of
infrainguinal angioplasty. In the group treated with le-
sions classified as TASC A/B, 6-month primary and
secondary patency was 100%. In contrast, TASC C/D
lesions had only 64% primary and 74% secondary pa-
tency. Kudo et al4 also determined that TASC D lesions
were predictive of decreased patency after angioplasty for
CLI. Although other authors have concluded that TASC
criteria did not predict outcome after infrainguinal per-
cutaneous intervention, we determined that TASC crite-
ria did predict outcomes in our cohort of patients.15
Similarly, patients with more advanced disease, SVS
grades 4 to 6, had significantly reduced primary and sec-
ondary patency at 6 months of 62% and 73% vs 100% and
100% for grades 2 to 3. The improvement after repeat
intervention is an important factor, repeat interventions are
generally well tolerated and are not usually more compli-
cated than primary interventions.
Given the rate of reocclusion, we believe that duplex
ultrasound surveillance is important after peripheralplaque excision. Our group has a substantial experience
with protocol-driven duplex ultrasound surveillance, and
we believe that these patients should be entered into
such a protocol.16-18 Half of the failures of plaque exci-
sion were detected and ultimately intervened upon based
on duplex testing. As our indications continue to expand
for plaque excision, duplex imaging will no doubt be
increasingly important in surveillance as prior work on
atherectomy demonstrated an increased rate of reocclu-
sion and restenosis.14
This study is certainly not without limitations. All of
the cases were performed at a single center by a single
surgeon and therefore may not be reproducible. Patients
were not compared with another treatment modality nor
were they randomized. Not all patients participated in a
follow-up surveillance protocol. Early results prohibit
statements about the long-term adequacy of atherec-
tomy for selected patients. The patient population was
somewhat heterogeneous in that one third were patients
with claudication, and difficulty arises when attempting
to compare patients with claudication with those with
CLI.
CONCLUSIONS
Plaque excision with the Silverhawk device is feasible
in a wide spectrum of patients with peripheral arterial
occlusive disease. Initial technical success rates are high,
and periprocedural morbidity and mortality rates are
lower than surgical bypass. Patency rates in patients with
claudication and with TASC A and B lesions approach
100% at 1 year. In patients with CLI and more complex
lesions (TASC C and D), primary patency rates are
significantly reduced. Despite these findings, a number
of lesions can be secondarily treated with endovascular
techniques, improving assisted and secondary patency
rates to 70%. Furthermore, limb salvage rates of 86% are
equivalent to those reported after bypass and other en-
dovascular interventions.4,18 Although plaque excision
can be considered for first-line treatment of claudication
and CLI, further studies are warranted to determine the
optimal treatment strategy in patients with CLI and
complex lesions (TASC D) in whom surgical revascular-
ization is not considered high risk.19
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